Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 7/20 | 0.55 |
| ▸ | NPC1 | O15118 | 4/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | ITGB2 | P05107 | 6/20 | 0.54 |
| ▸ | ICAM1 | P05362 | 6/20 | 0.54 |
| ▸ | ITGAL | P20701 | 6/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | BACE1 | P56817 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4276363 | 1.00 | RAB9A (0.55) | RAB9ANPC1TDP1ITGB2ICAM1 | |
| SCHEMBL13879628 | 0.88 | ALDH1A1 (0.57) | RAB9ANPC1L3MBTL1BACE1HPGD | |
| SCHEMBL4290343 | 0.86 | RAB9A (0.53) | RAB9ANPC1ITGB2ICAM1ITGAL | |
| SCHEMBL4290348 | 0.86 | RAB9A (0.53) | RAB9ANPC1ITGB2ICAM1ITGAL | |
| SCHEMBL13879606 | 0.82 | ITGAL (0.57) | RAB9AITGB2ICAM1ITGALL3MBTL1 | |
| SCHEMBL4286051 | 0.80 | GPR183 (0.46) | RAB9AITGB2ICAM1ITGALL3MBTL1 | |
| SCHEMBL4286044 | 0.80 | GPR183 (0.46) | RAB9AITGB2ICAM1ITGALL3MBTL1 | |
| SCHEMBL4290317 | 0.80 | RAB9A (0.56) | RAB9ANPC1ITGB2ICAM1ITGAL | |
| SCHEMBL4290314 | 0.80 | RAB9A (0.56) | RAB9ANPC1ITGB2ICAM1ITGAL | |
| SCHEMBL13879604 | 0.78 | CYP3A4 (0.69) | KDM4EBACE1HPGDALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099186-A1 | INHIBITORS OF VIRAL REPLICATION | INTERMUNE, INC. | 2009-04-16 | — | — | US | disclosed |
| US-20090099186-A1 | INHIBITORS OF VIRAL REPLICATION | INTERMUNE, INC. | 2009-04-16 | — | — | US | disclosed |
| US-20090099186-A1 | INHIBITORS OF VIRAL REPLICATION | INTERMUNE, INC. | 2009-04-16 | — | — | US | disclosed |
| WO-2007047146-A2 | INHIBITORS OF VIRAL REPLICATION | INTERMUNE, INC. (US) | 2007-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099186-A1 | INHIBITORS OF VIRAL REPLICATION | EIF2AK2, HAVCR2, RTF2 | RAB9A 3148/4885NPC1 680/4885TDP1 3859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.